Erythropoietin promotes hippocampal mitochondrial function and enhances cognition in mice by Jacobs, Robert A et al.








Erythropoietin promotes hippocampal mitochondrial function and enhances
cognition in mice
Jacobs, Robert A ; Aboouf, Mostafa A ; Koester-Hegmann, Christina ; Muttathukunnel, Paola ;
Laouafa, Sofien ; Arias-Reyes, Christian ; Thiersch, Markus ; Soliz, Jorge ; Gassmann, Max ; Schneider
Gasser, Edith M
Abstract: Erythropoietin (EPO) improves neuronal mitochondrial function and cognition in adults after
brain injury and in those afflicted by psychiatric disorders. However, the influence of EPO on mi-
tochondria and cognition during development remains unexplored. We previously observed that EPO
stimulates hippocampal-specific neuronal maturation and synaptogenesis early in postnatal development
in mice. Here we show that EPO promotes mitochondrial respiration in developing postnatal hippocam-
pus by increasing mitochondrial content and enhancing cellular respiratory potential. Ultrastructurally,
mitochondria profiles and total vesicle content were greater in presynaptic axon terminals, suggesting
that EPO enhances oxidative metabolism and synaptic transmission capabilities. Behavioural tests of
hippocampus-dependent memory at early adulthood, showed that EPO improves spatial and short-term
memory. Collectively, we identify a role for EPO in the murine postnatal hippocampus by promoting mi-
tochondrial function throughout early postnatal development, which corresponds to enhanced cognition
by early adulthood.
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Erythropoietin (EPO) improves neuronal mitochondrial function and cognition in adults after
brain injury and in those afflicted by psychiatric disorders. However, the influence of EPO on
mitochondria and cognition during development remains unexplored. We previously
observed that EPO stimulates hippocampal-specific neuronal maturation and synaptogenesis
early in postnatal development in mice. Here we show that EPO promotes mitochondrial
respiration in developing postnatal hippocampus by increasing mitochondrial content and
enhancing cellular respiratory potential. Ultrastructurally, mitochondria profiles and total
vesicle content were greater in presynaptic axon terminals, suggesting that EPO enhances
oxidative metabolism and synaptic transmission capabilities. Behavioural tests of
hippocampus-dependent memory at early adulthood, showed that EPO improves spatial and
short-term memory. Collectively, we identify a role for EPO in the murine postnatal hippo-
campus by promoting mitochondrial function throughout early postnatal development, which
corresponds to enhanced cognition by early adulthood.
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rythropoietin (EPO) continues to develop as a promising
neuroprotective agent with widespread clinical relevance1,2
since the discovery that EPO and its receptor (EPOR) are
expressed in the central nervous system (CNS)3. EPO can mediate
neuroprotection following traumatic injury, hypoxia-ischemic
insults, excitotoxicity, inflammatory brain injury4,5, and retinal
protection following hypoxia6 or vascular injury7,8. EPO prevents
hippocampal neurodegeneration and attendant cognitive
impairment in rodents presenting with diabetes9 or Alzheimer-
like diseases10,11 as well as reduces long-term spatial-memory
deficits across various animal models of neonatal brain
injury12,13. In humans, EPO has been shown to enhance memory
retrieval by increasing hippocampal plasticity4,14–17 and
improving neurogenesis10,14,18–20 in both healthy individuals and
those affected by various neurodegenerative diseases and
dementia. The neuroprotective potential of EPO also extends to
neonatology, since it has been reported to reduce perinatal brain
injury21,22 and improve neurological outcomes in very prema-
turely born neonates21,23,24.
EPO neuroprotection involves the activation of multiple
downstream signaling pathways, including extracellular signal-
regulated kinases 1 and 2 (Erk1/2) and phosphatidylinositol 3-
kinase (PI3K)/protein kinase B (AKT)13, which concomitantly
upregulate anti-apoptotic, anti-inflammatory, anti-oxidative, and
anti-cytotoxic pathways13,21,22. The cellular effects of these
pathways (i.e., apoptosis, redox balance, cytotoxicity, and
inflammation) all relate through their dependence on mito-
chondrial control. Indeed, EPO has been shown to enhance
mitochondrial biogenesis through AKT signaling in
cardiomiocytes25,26, and activation of Erk1/2 promotes dynamin-
related protein 1-dynamin 1 (DRP1-DNM1)-dependent mito-
chondrial fission and cell survival27,28.
The importance of mitochondria in neuronal development and
function is highlighted by their role in promoting neuronal dif-
ferentiation, neurotransmission, and synaptic pruning29. The
close relationship mitochondria share with neurodevelopment
and cognition is also evidenced by the influence of mitochondrial
morphology and function on synaptic vesicle pool regulation,
spatial memory, and working memory throughout neuronal
maturation30,31. EPO has been reported to support neuronal
mitochondria and prevent memory impairment in animal models
of multiple sclerosis, sleep deprivation, neurodegeneration, and
brain injury32–36. Furthermore, EPO prevents neurobehavioral
deficits in the hippocampus of young rats exposed to intermittent
hypoxia37 as well as a murine model of sleep apnea38 by mana-
ging cellular oxidative stress. However, questions relating to the
influence of EPO regulating brain mitochondria during devel-
opment remain to be answered.
We have recently reported that EPO signals on CA1 pyramidal
cells in the hippocampus and improves hippocampal postnatal
neuronal maturation by reducing cell death and promoting
synaptogenesis39. Putative mitochondrial mechanism(s) in pro-
moting these processes are unexplored. Additionally, whether
EPO improves hippocampal-mediated cognitive function in
healthy animals remains unknown.
Accordingly, the aim of this research was to analyze the
influence of EPO on brain mitochondria throughout postnatal
development and examine whether postnatal EPO availability
influences cognition in mice. This work demonstrates that EPO in
the CNS activates Erk1/2 and AKT pathways in the hippocampus.
Constitutive cerebral EPO overexpression and high-dose intra-
peritoneal (i.p.) administration of EPO during three consecutive
days, coincides with increased mitochondria number, size, and
respiration. EPO overexpression increases mitochondria number
and function at postnatal ages (P) 14 to 21. The postnatal rise in
mitochondria was also identified with electron microscopy (EM)
in presynaptic axon terminals, along with higher vesicle number,
which suggests that EPO promotes neuronal mitochondrial
function and enhances the putative reserve pool of the synaptic
vesicles. Transcriptional signals controlling mitochondrial bio-
genesis and dynamics were altered with EPO-associated increases
in peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC1α), mitofusin 1 (MFN1), mitofusin 2 (MFN2), and
DRP1-DNM1. Thus, EPO-mediated activation of Erk1/2 and
AKT pathways throughout postnatal development corresponds
with attendant improvements in mitochondrial function and
hippocampal-specific cognition.
Results
Respirometry, mRNA, and protein analyses in transgenic mice
constitutively overexpressing recombinant human (rh) EPO
specifically in the brain (Tg21) and wildtype (WT) control mice
were done across postnatal ages (P): 3, 7, 14, 21, and 60 (Fig. 1a).
EM ultrastructural analysis was done at P14, and behavioral
analysis was performed during early adulthood (P45–60) in both
genotypes (Fig. 1a).
EPO overexpression in the CNS activates Erk1/2 and AKT
pathways in the hippocampus. Measurements of total hippo-
campal EPO expression was greater in Tg21 mice at all postnatal
ages (2-way ANOVA, F(1,91)= 533, p < 0.0001, Fig. 1b). Speci-
fically, the average EPO protein expression in WT hippocampus
was 38.7 ± 3 pg/mg immediately after birth (P1), which then
decayed rapidly with postnatal development to 6.3 ± 2 pg/mg at
adulthood. Alternatively, hippocampal EPO expression in Tg21
mice was 2.3-fold higher at P1 (89.5 ± 2 pg/mg), 4.5-fold higher at
P3 (134.5 ± 2 pg/mg), 13-fold higher at P7 (181.3 ± 3 pg/mg), 16-
fold higher at P14 (88.9 ± 4 pg/mg), and 10-fold higher at P21
(66.4 ± 3 pg/mg) (Fig. 1b). Thereafter, EPO overexpression in
Tg21 animals diminished to a 4-fold higher concentration (22 ± 6
pg/mg) than WT in adulthood (P60). No differences were
observed between genotypes regarding spleen weight (WT, 55.1 ±
14 mg vs. Tg21, 54.9 ± 23 mg; student’s t-test, p= 0.99), hema-
tocrit (WT, 39 ± 7% vs Tg21, 39.4 ± 5%; student’s t-test, p= 0.88),
plasma hemoglobin (WT, 15.2 ± 1 vs Tg21, 16.2 ± 1; student’s t-
test, p= 0.07), and plasma EPO concentrations (WT, 45.1 ± 23 vs
Tg21, 43. 5 ± 18 pg/mL; student’s t-test, p= 0.88) measured at
P21 (Supplementary Fig. 1a). Murine EPO (mEPO) expression
was hardly detected in the brain of WT and Tg21 mice while
rhEPO was only detected in the brain of Tg21 mice (2-way
ANOVA, F(1,16)= 275, p < 0.0001; Supplementary Fig. 1b).
Constitutive overexpression of rhEPO was restricted to the brain
of Tg21 groups (P5 and P21) (1-way ANOVA brain, F(2,9)=
30.57, p < 0.0001) with a minor transient elevation detected in the
liver at P5 but no differences in kidney or spleen (Supplementary
Fig. 1c).
Hippocampal EPOR mRNA expression, assessed by RT-PCR
analysis, increased throughout postnatal development in both
WT and Tg21 mice reaching a 4-fold increased expression at P60
compared to P3 (2-way ANOVA, F(4,50)= 53.11, p < 0.0001;
Fig. 1c) with no significant differences between genotypes (2-way
ANOVA, F(1,50)= 1.51, p= 0.22; Fig. 1c). EPOR mRNA
expression was 8-fold higher in the spleen than hippocampus at
P60 in both genotypes (2-way ANOVA, F(1,18)= 18.67, p=
0.0004, Supplementary Fig. 1d), suggesting that EPO sensitivity in
the hippocampus is lower than that of hemopoietic tissue.
Cortical EPOR mRNA expression was negligible after birth and
throughout development with no differences between genotypes,
apart from a transient rise in WT mice at P14 (2-way ANOVA, F
(1,38)= 2.77, p= 0.1; Supplementary Fig. 1e). Thus, postnatal
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EPOR transcription in the brain is largely specific to the
hippocampus, reaching a plateau towards adulthood (P21).
Intracellular EPO/EPOR signaling acts through multiple path-
ways including Erk1/2 and AKT, with both pathways involved in
regulating mitochondrial biogenesis, mitochondrial dynamics,
metabolic control, and cell fate25,27. Therefore, we analyzed the
control of hippocampal EPO overexpression on Erk1/2 and AKT
activation throughout postnatal development by western blot
(Fig. 1d–k and Supplementary Fig. 3). Total Erk1/2 (Fig. 1d, e)
and phosphorylated (p)Erk1/2 (Fig. 1f, g) band intensities were
normalized to vinculin expression. There were no differences in
total Erk1/2 protein between WT and Tg21 mice (2-way
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ANOVA, F(1,24)= 1.24, p= 0.28; Fig. 1e). In contrast, pErk1/2
was at least 2-fold higher in Tg21 mice across all postnatal ages.
The greatest difference in pErk1/2 between genotypes, identified
primarily by the 42 kDa band, occurred at postnatal ages P3 and
P21 (2-way ANOVA, F(1,24)= 63.54, p < 0.0001, Fig. 1g).
Fluorescent western blot analyses of total AKT (red, Fig. 1h and
Supplementary Fig. 2) and pAKT (green, Fig. 1j and Supplemen-
tary Fig. 2) showed an 8-fold greater expression of pAKT over
total AKT at P3, the 4-fold difference a P7, and a 2-fold difference
at P14 and P21 in Tg21 mice (2-way ANOVA, F(1,16)= 43.92, p
< 0.0001; Fig. 1k) with no differences in total AKT between
genotypes (2-way ANOVA, F(1,16)= 1.35, p= 0.26; Fig. 1i). No
significant changes in total Erk1/2 (2-way ANOVA, F(3,24)=
0.43, p= 0.73, Fig. 1e) and in AKT (2-way ANOVA, F(3,16)=
2.72, p= 0.08; Fig. 1i) were observed during development in
either genotype. These data suggest that EPO-dependent activa-
tion of Erk1/2 and AKT pathways occurs in the hippocampus
without influencing the total protein expression of these
transcriptional regulators. pAKT did not vary in Tg21 or WT
throughout development (2-way ANOVA, F(3,16)= 0.72, p=
0.55; Fig. 1k). Moreover, pErk1/2 was higher at P3 and P21 when
compared to P7 and P14 in both genotypes (2-way ANOVA, F
(3,16)= 46.99, p < 0.0001; Fig. 1g). Since activation of Erk1/2 and
AKT are associated with mitochondrial metabolism and
dynamics25,27,28, we examined whether EPO-mediated activation
of Erk1/2 and AKT influences mitochondrial morphology and
function.
EPO overexpression in the CNS promotes mitochondrial
respiration in the postnatal hippocampus. We used high-
resolution respirometry to assess respiratory control in hippo-
campal tissue from both Tg21 and WT control mice with
representative respirometric traces collected from P21 WT (top)
and Tg21 (bottom) animals illustrated in Fig. 2a. Mass-specific
NADH-linked respiration (PCI; 2-way ANOVA, F(1.66)= 15.74,
p= 0.002; Fig. 2b) and non-coupled NADH- and succinate-
linked respiration (ECI+CII; 2-way ANOVA, F(1,66)= 22.22, p <
0.0001; Fig. 2d) were higher at P14 and P21 in the Tg21 mice.
Maximal rates of NADH- and succinate-linked respiration
(PCI+CII; F(1,66)= 9.21, p= 0.003; Fig. 2c) were also higher in
Tg21 mice vs WT controls at P21.
There was also an effect of age on mass-specific oxygen
consumption rates (OCR), with an increase observed as age
advanced in WT (1-way ANOVA, F(4,35)= 25.2, p < 0.0001;
Fig. 2e) and Tg21 (1-way ANOVA, F(4,35)= 24.0, p < 0.0001;
Fig. 2f) animals. In general, age-associated increases in hippocampal
OCR occurred earlier and more abruptly in the postnatal
development of Tg21 mice between P7 and P14 (Fig. 2f) when
compared to their WT counterparts that demonstrated a more
gradual increase from P3 to P21 (Fig. 2e). Specific intra-genotypic
differences in respiratory states across ages are shown in Fig. 2e, f
for WT and Tg21 mice, respectively. Collectively, these data suggest
that overexpression of cerebral EPO facilitates greater hippocampal
respiratory capacity earlier in postnatal development.
Mass-specific respiration also increased with age throughout
postnatal development in the cortex (WT: 1-way ANOVA,
F(2,14)= 5.6, p= 0.02, Tg21: 1-way ANOVA, F(2,13)= 10.15,
p= 0.002, Supplementary Fig. 3a) and in WT brainstem (1-way
ANOVA, F(2,18)= 11.55, p= 0.0006, Supplementary Fig. 3b) but
no differences between genotypes were identified (2-way
ANOVA, F(1,30)= 0.15, p= 0.7, Supplementary Fig. 3a and 2-
way ANOVA, F(1,36)= 0.0002, p= 0.99, Supplementary Fig. 3b,
respectively). This suggests that EPO-mediated influence over
mitochondria is limited to the hippocampus.
EPO overexpression in the CNS facilitates changes in respira-
tory control by increasing mitochondrial content in the hip-
pocampus during postnatal development. Cytochrome c oxidase
(COX; complex IV) activity, validated as a surrogate of mito-
chondrial content in human skeletal muscle40, differed between
genotypes throughout postnatal development with higher measures
observed at P14, P21, and P60 in Tg21 animals compared to WT
(2-way ANOVA, F(1,66)= 36.77, p < 0.0001; Fig. 3a). Like
respiratory control (Fig. 2), an age-dependent increase in COX
activity was observed in both genotypes with the greatest increases
in COX activity occurring between P7 and P14 in Tg21 and
between P14 and P21 in WT mice (2-way ANOVA, F(4,66)=
45.79, p < 0.0001; Fig. 3a). Mitochondria-specific respiratory ana-
lysis (mass-specific respiration normalized to a surrogate of mito-
chondrial content, e.g., COX activity) helps distinguish qualitative
alterations in respiratory control from quantitative differences dri-
ven primarily by mitochondrial content. When normalizing mass-
specific OCR to COX, respiratory differences between genotypes
were lost (Fig. 3b–f). These data suggest that mass-specific OCR
differences between genotypes are most likely attributable to
quantitative disparities in mitochondrial content as opposed to
qualitative variations in mitochondrial function.
To further test the differences in hippocampal mitochondria
between genotypes, we examined the ratio of mitochondria DNA
(mtDNA, represented by ND1 gene) normalized to nuclear DNA
(nDNA, represented by β2M) by qPCR as well as the expression
of various mitochondrial proteins with Western blots across
Fig. 1 Erythropoietin (EPO) overexpression in the central nervous system (CNS) activates Erk1/2 and AKT pathways in the hippocampus. a Schematic
diagram of the experimental design used for wildtype (WT) and transgenic (Tg21) animals that constitutively overexpress cerebral EPO. b Total (murine
and recombinant human) EPO protein expression in the hippocampus across postnatal (P) ages: 1, 3, 7, 14, 21, and 60. EPO is greatly overexpressed in the
hippocampus of Tg21 mice throughout postnatal development, decaying to its lowest difference compared to age-matched WT controls by adulthood
(P60); 2-way ANOVA, F(1,91)= 533, ****p < 0.0001. c EPOR mRNA expression in the hippocampus of WT and Tg21 mice across postnatal ages P: 3, 7, 14,
21, and 60, normalized to GAPDH. An age-induced increase in EPOR is shown with no difference between genotypes; 2-way ANOVA, F(1,50)= 1.51, p=
0.22. d Representative uncropped western blot images of total Erk1/2 protein expression across postnatal ages P: 3, 7, 14, and 21 in WT and Tg21 mice with
a vinculin loading control. e Quantification of total Erk1/2 protein shows no differences between genotypes; 2-way ANOVA, F(1,24)= 1.24, p= 0.28. f
Representative uncropped western blot images of phosphorylated (p)Erk1/2 protein expression across postnatal ages P: 3, 7, 14, and 21 in WT and Tg21
mice with vinculin load control. g Quantification of pErk1/2 shows highest levels of phosphorylation at P3 and P21 in both genotypes and 2-fold
higher activation in the Tg21 mice across all measured ages; 2-way ANOVA, F(1,24)= 63.54, ****p < 0.0001, with multiple comparison: *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001. h Representative image of total AKT protein expression with β-actin loading control (red; top panel) in WT and Tg21
mice at postnatal ages P: 3, 7, 14, and 21. i Quantification of total AKT shows no change throughout development or difference between genotypes; 2-way
ANOVA, F(1,16)= 1.35, p= 0.26. j Representative image of pAKT (green) superimposed over total AKT (red) in WT and Tg21 mice at postnatal ages P: 3,
7, 14, and 21. k Quantification of pAKT shows the lowest levels of phosphorylation in WT mice at P3 with a gradual increase until P21, and Tg21 animals
demonstrate similarly higher values at all ages; 2-way ANOVA, F(1,16)= 43.92, ****p < 0.0001, with multiple comparisons: *p < 0.05, ***p < 0.001.
Barplots with SD bars.
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postnatal ages (Fig. 4). mtDNA/nDNA ratio was higher in Tg21
mice at P14 and P21 (2-way ANOVA, F(1,18)= 26.19, p <
0.0001; Fig. 4a). Furthermore, higher voltage-dependent anion
channel 1 (VDAC1) expression, the most abundant protein of the
outer membrane of mitochondria, was observed in Tg21 mice
(Fig. 4b–c and Supplementary Fig. 4) with 4.9-fold higher protein
expression at P14 and 1.6-fold more protein at P21 compared to
WT (2-way ANOVA, F(1,16)= 73.94, p < 0.0001; Fig. 4c).
Mitochondrial proteins specific to the electron transport system
were also higher in Tg21 mice compared to WT at various stages
throughout postnatal development (Fig. 4d–i). Specifically,
complex I (NDUFB8) was 2.7-fold higher at P7 and 4.3-fold
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higher at P14 (2-way ANOVA, F(1,24)= 26.69, p < 0.0001;
Fig. 4e), complex II (SDHB) was 2.2-fold higher at P21 (2-way
ANOVA, F(1,24)= 10.93, p= 0.003; Fig. 4f), complex III
(UQCRC2) was 13.7-fold higher at P7 (2-way ANOVA, F(1,24)
= 62.26, p < 0.0001; Fig. 4g), complex IV (COX-IV) was 6.9-fold
higher at P7, 3.9-fold higher at P14, and 2-fold higher at both P21
and P60 (2-way ANOVA, F(1,24)= 131.9, p < 0.0001; Fig. 4h),
and complex V (ATP5A) was 3.2-fold higher at P7 in Tg21 mice
(2-way ANOVA, F(1,24)= 15.24, p= 0.0007; Fig. 4i).
High-dose intraperitoneal (i.p.) administration of EPO
increases hippocampal Erk1/2 and AKT activity as well as
mitochondrial respiration and content. To verify that hippo-
campal increases in pErk1/2, pAKT, respiratory rates, and mito-
chondrial content are not due to a non-specific effect of our
transgenic (Tg21) model, WT mice received (50 μl) i.p. treatments
of either saline or rhEPO (5 IU/g) for three consecutive days at the
age of weaning (P23-25, Fig. 5a). This dose of EPO is high enough
to facilitate transportation across the blood brain barrier41. At P26,
twenty-four hours after the last i.p. injection, hippocampal Erk1/2
and AKT activation, respiratory control, and indices of mitochon-
drial content were assessed (Fig. 5c–l and Supplementary Fig. 5).
Systemic administration of EPO resulted in the canonical increase
in hematocrit from 38% to 50.4% (Student’s t-test, p < 0.0001;
Fig. 5b) that was not observed in saline-treated animals. While total
AKT protein was higher in EPO-treated mice (Student’s t-test, p=
0.049; Fig. 5d), there was no difference in Erk1/2 expression
between EPO and saline-treated groups (Student’s t-test, p= 0.26;
Fig. 5e). pAKT and pErk1/2 were higher in EPO-treated mice
(Student’s t-test; p= 0.03, Fig. 5h and p= 0.01, Fig. 5i, respectively).
EPO-treated mice expressed more mitochondrial protein including
VDAC1 expression (Student’s t-test, p= 0.004; Fig. 5f) and COX
activity (Student’s t-test, p= 0.0006; Fig. 5j) as well as mass-specific
PCI, PCI+CII, and ECI+CII OCR (2-way ANOVA, F(1,56)= 40.27, p
< 0.0001; Fig. 5k). When normalizing mass-specific respiration to
COX, the differences between treatments were lost (2-way ANOVA,
F(1,56)= 0.77, p= 0.38; Fig. 5l), further confirming that EPO
increases mitochondrial content in the hippocampus. Collectively,
these results are consistent with the effects of cerebral over-
expression of EPO in the Tg21 line.
EPO overexpression in CNS upregulates PGC1-1α, influences
mitochondria dynamics, and ultimately increases mitochon-
dria and vesicle number in presynaptic terminals. Transcrip-
tional expression of peroxisome proliferator-activated receptor-
gamma coactivator 1α (PGC1α) throughout postnatal develop-
ment (P3, P7, P14, P21) was assessed via RT-PCR in WT and
Tg21 mice. An age-dependent increase in PGC1α mRNA was
evident in both genotypes with a 2.2-fold increase at P14-P21
compared to P3-P7 (2-way ANOVA, F(3,18)= 46.93, p < 0.0001;
Fig. 6a), which generally corresponds with the age-dependent
increases in hippocampal respiration (Fig. 2e, f). Moreover,
transcriptional expression of PGC1α was higher in Tg21 com-
pared to WT at P21 (Student’s t-test, P21, p= 0.03; Fig. 6a).
Transcriptional expression of autophagy-related gene 5 (ATG5)
showed an age-dependent increase in expression without any
difference between genotypes (2-way ANOVA, F(3,24)= 11.98,
p= 0.001; Fig. 6b).
Transcriptional control of mitochondrial pro-fusion, mitofusin 1
(MFN1) and mitofusin 2 (MFN2), as well as pro-fission, DRP1-
DNM1 and dynamin 2 (DNM2), signaling was assessed via RT-PCR
throughout postnatal development in WT and Tg21 mice. A 2.6-
fold age-dependent increase in MFN2 mRNA was observed in WT
and Tg21 at P14 and P21 over P3 and P7 (2-way ANOVA, F(3,24)
= 48.59, p < 0.0001; Fig. 6c) with greater expression in Tg21 vs WT
animals at P21 (2-way ANOVA, F(1,24)= 7.2, p= 0.01; Fig. 6c).
MFN1 mRNA did not change with age but Tg21 animals
demonstrated greater expression at P21 (2-way ANOVA, F(1,24)
= 1.143, p= 0.01; Fig. 6d). No age-dependent changes or genotype-
specific differences in DNM2 mRNA were observed (2-way
ANOVA, F(1,24)= 0.37, p= 0.54; Fig. 6e). While transcriptional
expression of DRP1-DNM1 also did not show age-dependent
changes in either genotype, higher mRNA was identified in Tg21 vs
WT mice at P21 (2-way ANOVA, F(1,24)= 8.834, p= 0.0066;
Fig. 6f). These data suggest that EPO upregulates transcriptional
signaling for mitochondrial biogenesis via PGC1α and alters
mitochondrial dynamics in the hippocampus.
Mitochondrial profiles in the hippocampus, along with
quantitative analysis of presynaptic mitochondria content and
vesicle number, were examined by electron microscopy (EM;
Fig. 6g–k). The upregulation of hippocampal mitochondria as
suggested by COX activity (Fig. 3a), mtDNA/nDNA (Fig. 4a),
mitochondrial protein (Figs. 4 and 5), and PGC1α mRNA
(Fig. 6a) was confirmed via EM as evidenced by a higher number
of mitochondria structures (Fig. 6g, arrows and Fig. 6h; Student’s
t-test, p= 0.036) as well as greater size (Student’s t-test, p= 0.002;
Fig. 6i). Importantly, total mitochondrial mass and vesicle
number were both higher in presynaptic axon terminals of
Tg21 mice irrespective of the synapse type (symmetric or
asymmetric) (Fig. 6g insets, Student’s t-test, p= 0.0043, Fig. 6j;
and Student’s t-test, p < 0001, Fig. 6k). These latter results suggest
Fig. 2 EPO overexpression in the CNS influences mass-specific respiratory control in the postnatal hippocampus. a Representative respirometric traces
from a WT (top panel) and a Tg21 (bottom panel) hippocampal tissue, which illustrates the change in oxygen concentration (nmol·ml−1, left y axis, blue
line) and oxygen flux per mass (pmol O2/s * mg ww, right y axis, red line) in hippocampal tissue at P21. Respiratory states were achieved through the
titration of various substrates, inhibitors, as well as a protonophore. The order of respiratory state analysis from beginning to end (left-to-right) with the
respective substrates, inhibitors, or protonophores added, as fully explained in the methods, consisted of: leak without adenylates (LN; addition of malate
and octanoylcarnitine); coupled respiration with maximal electron input specific to mitochondrial complex I (PCI; addition of ADP, pyruvate, and glutamate);
maximal rates of coupled respiration with electron input specific to complex I and II (PCI+CII; addition of succinate); maximal non-coupled respiration (E)
with electron input from complex I and II (ECI+CII; steps of carbonyl cyanide p-trifluoromethoxy phenylhydrazone, FCCP, addition until respiration ceases to
increase); non-coupled respiration with maximal electron input specific to mitochondrial complex II (ECII; addition of rotenone); and non-mitochondrial
residual oxygen consumption (ROX; addition of antimycin). Following respiratory state analysis, ascorbate and N,N,N′,N′-tetramethyl-1,4-benzenediamine,
dihydrochloride (TMPD) were simultaneously added to assess cytochrome c oxidase (COX; complex IV) activity. bMass-specific PCI respiration in WT and
Tg21 mice, showing higher oxygen consumption rates (OCR) at P14 and P21 in Tg21 mice; 2-way ANOVA, F(1.66)= 15.74, **p= 0.002. cMass-specific PCI
+CII respiration in WT and Tg21 mice, showing higher OCR at P21 in Tg21 mice; 2-way ANOVA, F(1,66)= 9.21, **p= 0.003. d Mass-specific ECI+CII in WT
and Tg21 mice, showing higher OCR at P14 and P21 in Tg21 mice; 2-way ANOVA, F(1,66)= 22.22, ****p < 0.0001. eMass-specific respiration for WT mice
at postnatal ages of P: 3, 7, 14, 21, and 60. An age-dependent effect is observed in PCI, PCI+CII, and ECI+CII; 1-way ANOVA, F(4,35)= 25.2, ****p <0.0001.
f Mass-specific respiration for Tg21 mice at postnatal ages of P: 3, 7, 14, 21, and 60. An age-dependent effect is observed in PCI, PCI+CII, and ECI+CII; 1-way
ANOVA, F(4,35)= 24.0, ****p < 0.0001, with multiple comparisons: **p= 0.002, ***p < 0.001, ****p < 0.0001. Barplots with SD bars.
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a possible increase in synaptic transmission influencing hippo-
campal function in Tg21 mice.
EPO overexpression in CNS enhances hippocampal-dependent
spatial navigation and short-term memory
Morris water maze (MWM) test. Young adult mice from both
genotypes successfully learned to find the hidden platform during
the acquisition phase, as demonstrated by the escape latency and
swimming path length (Fig. 7a, upper panels). A shorter escape
latency was observed in Tg21 mice beginning on day 2 (d2) (2-
way ANOVA, F(1,22)= 28.18, p < 0.001; Fig. 7a upper left panel).
The swimming path length was not different between genotypes
during the acquisition phase (2-way ANOVA,
F(1,22)= 0.85, p= 0.36; Fig. 7a, upper middle panel). However,
the indication of enhanced learning in Tg21 compared to WT
controls was evident across days with Tg21 mice showing longer
swim paths on d1, negligible differences in swim paths on d2, and
shorter swim paths on d3 and d4. Additionally, Tg21 mice
exhibited faster swim speeds than WT controls across all days (2-
way ANOVA, F(1,22)= 62.4, p < 0.0001; Fig. 7a upper right
Fig. 3 EPO overexpression in the CNS influences respiratory control by increasing mitochondria in the postnatal hippocampus. a Cytochrome C oxidase
activity (COX, pmol O2/s * mg ww) in the hippocampus of WT and Tg21 throughout postnatal development. Tg21 mice show higher COX activity at P14,
P21, and P60; 2-way ANOVA, F(1,66)= 36.77, ****p < 0.0001, with multiple comparisons: *p < 0.05, and ***p < 0.001. Mitochondria-specific respiration
for b PCI; c PCI+CII; and d ECI+CII throughout postnatal development in WT vs Tg21 mice. An increase in respiration throughout postnatal development is
observed along with an increase in mitochondrial content in both genotypes for all respiratory states. No differences between genotypes are observed: (2-
way ANOVA; PCI, F(1,66)= 2.40, p= 0.13); PCI+CII, F(1,66)= 2.28, p= 0.13; and ECI+CII, F(1,66)= 0.73, p= 0.40. Mass-specific oxygen consumption rates
(OCR) relative to COX (%) in e WT mice and f Tg21 mice for leak respiration without adenylates (LN); complex I (PCI); complex I and II (PCI+CII); and
maximal non-coupled respiration with electron input from complex I and II (ECI+CII) at postnatal ages of P: 3, 7, 14, 21, and 60. Mass-specific respiratory
differences between genotypes are lost when normalizing to COX, a surrogate of mitochondrial content; 1-way ANOVA: WT, F(4,15)= 0.24, p= 0.91; and
Tg21, F(4,15)= 0.45, p= 0.76. Barplots with SD bars.
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Fig. 4 EPO overexpression in the CNS increases mitochondrial DNA, voltage-dependent anion channel 1 (VDAC1), and electron transport system
proteins in the hippocampus throughout postnatal development. a Fold change in mitochondrial (mt) DNA over nuclear (n) DNA ratio in WT and Tg21
mice across postnatal ages P: 7, 14, and 21 shows higher mtDNA to nDNA in Tg21 mice; 2-way ANOVA, F(1,18)= 26.19, ****p < 0.0001, with multiple
comparisons: *p < 0.05 and **p < 0.01. b Representative images of total VDAC1 with vinculin as a loading control across postnatal ages P: 3, 7, 14, and 21.
c Quantification of VDAC1 protein expression normalized to vinculin and to WT at P3; 2-way ANOVA, F(1,16)= 73.94, ****p < 0.0001. d Representative
uncropped images of mitochondrial electron transport system protein expression and against β-actin as loading control in WT and Tg21 mice across
postnatal ages P: 7, 14, 21, and 60. e Quantification of protein expression for mitochondrial complex I (CI), NADH dehydrogenase subunit NDUFB8; 2-way
ANOVA, F(1,24)= 26.69, ****p < 0.0001; f mitochondrial complex II (CII), succinate dehydrogenase complex iron-sulfur subunit B (SDHB); 2-way
ANOVA, F(1,24)= 10.93, **p= 0.003; g mitochondrial complex III (CIII), ubiquinol–cytochrome c reductase core protein 2 (UQCRC2); 2-way ANOVA,
F(1,24)= 62.26,****p < 0.0001; hmitochondrial complex IV (CIV), cytochrome c oxidase (COX), subunit 1; 2-way ANOVA, F(1,24)= 131.9, ****p < 0.0001;
and i mitochondrial complex V (CV), ATP synthase alpha subunit (ATP5A); 2-way ANOVA, F(1,24)= 15.24, ***p= 0.0007. Mitochondrial protein
expression is higher in Tg21 mice at P7 (CIII, CIV, and CV), P14 (VDAC1, CI, and CIV), P21 (VDAC1, CII, and CIV), and P60 (CIV). Dotted lines represent
values of 1. Multiple comparisons: 2-way ANOVA: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Barplots with SD bars.
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panel). During the reversal trial (d5) (Fig. 7a lower panels), both
groups showed an increased preference for the training quadrant,
and this preference was stronger in Tg21 animals (2-way
ANOVA, F(1,22)= 10.5, p < 0.0001). Additionally, Tg21 mice
presented shorter escape latency (2-way ANOVA, F(1,22)= 10.8,
p < 0.001; Fig. 7a lower left panel), shorter swim path length
(2-way ANOVA, F(1,22)= 12.1, p < 0.01; Fig. 7a lower middle
panel), and faster swim speed (2-way ANOVA, F(1,22)= 18.56,
p < 0.0001; Fig. 7a lower right panel) when finding the new
hidden platform location. These results suggest that Tg21 mice
have improved spatial learning and memory compared to WT
controls.
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Novel object recognition (NOR). The cognitive impact of EPO on
recognition memory was assessed via novel object recognition
(NOR) tasks (Fig. 7b). Both Tg21 and WT mice were habituated
to learn the location and become familiar with two equal objects
over a single 5 min learning event. Subsequently, short-term and
long-term memory was examined when testing the recognition of
a novel object after 1 and 24 h inter-trial intervals (ITI), respec-
tively (Fig. 7b, upper panel). During the habituation phase, Tg21
animals explored the empty arena more intensively than WT
mice resulting in more total locomotor activity (4.96 ± 6.8 vs. 3.97
± 6 m/min, respectively, Student’s t-test, p < 0.001). During the
training phase, total object exploration time was similar between
genotypes. In the short-term memory test, both WT and Tg21
mice spent more time exploring the novel object. However, Tg21
mice exhibited a stronger preference for the novel object reflected
by an object discrimination index (equation (1)) above 0.5. Long-
term memory was then tested 24 h later when the mice were given
5 min in the arena with a novel displaced object. In this task, both
genotypes equally recognized the novel object with a similar
object discrimination ratio (equation (1)) of 0.28 ± 0.18 for WT
and 0.25 + 0.2 for Tg21 (2-way ANOVA, F(1,68)= 6.18, p=
0.01; Fig. 7b, lower panel). Although this test is not exclusively
hippocampal, as visual cues are involved in task analysis, it is a
valid test to assess cognition in young adult mice with the speed
in learning locations highlighting cognitive flexibility.
T-maze spatial working memory. Impact of EPO on spatial
working memory showed spontaneous alternation to be more
than 75% correct in both genotypes (Fig. 7c). Nevertheless, Tg21
mice were faster in learning the choice (10.13 ± 0.74 s for WT and
7.37 ± 0.70 s for Tg21; Student’s t-test, p= 0.0004), and had less
errors than WT in the second and third test of each. When the
ITI was 24 h, however, no difference between genotypes was
observed (t4–6; Student’s t-test, p= 0.4; Fig. 7c, bottom panel)
Thus, only an increase in short-term spatial working memory was
observed in Tg21 mice.
Collective, cognitive testing demonstrates that EPO over-
expression improves performance speed, hippocampal-mediated
spatial learning and memory, and short-term memory while long-
term memory remained unaltered.
Discussion
The aim of this research was to analyze the influence of EPO on
brain mitochondria throughout early postnatal development and
examine whether EPO availability improves cognition in mice.
Our primary findings reveal that EPO promotes postnatal
increases in hippocampal mitochondria, respiratory potential,
and enhances cognition. More specifically, elevated cerebral EPO
during early postnatal development increases hippocampal
pErk1/2 and pAKT while hastening local mitochondrial
maturation by approximately one week (~33% increase), which
functionally results in greater oxidative potential. Expedited
mitochondrial development in the hippocampus is also evident in
presynaptic terminals along with greater vesicle numbers, both of
which coincide with improved spatial and short-term memory at
early adulthood. Collectively, these findings add to the clinical
non-hematopoietic relevance of EPO on stimulating neural
development and cognition (see Fig. 8 for results summary).
EPO/EPOR signaling is dependent upon the concentration of
EPO and expression of EPOR. Expression of EPOR transcripts
increases throughout postnatal development in the hippocampus,
mainly in CA1 pyramidal neurons, with the greatest expression
achieved at weaning (P21)39. This observation was confirmed in
the current study, as EPOR mRNA increased throughout post-
natal development up to P21. Alternatively, postnatal EPOR
mRNA expression in cortical areas was mostly negligible. This
implies a role of EPO in the postnatal maturation of CA1 prin-
cipal neurons during the time of development when these cells
undergo dendritic arborization, axon growth, spine formation,
synaptogenesis42, and when GABAergic synapses form within the
postsynaptic populations of CA1 neurons43. A transient hippo-
campal hyperexcitability in the second postnatal week has been
reported as a result of axonal remodeling44. Hyperexcitability
causes brief episodes of local hypoxia in CA1 pyramidal
neurons45. Therefore, it is conceivable that these transient epi-
sodes of local hypoxia trigger EPO and EPOR production at this
age, enhancing synaptogenesis, circuit formation, and, conse-
quently, cognition. Evidence of a local hypoxic influence on the
expression of both EPO and EPOR in pyramidal cells, as well as
its impact in spine density, has been previously demonstrated46.
EPOR expression in developing embryonic mouse brain is similar
to adult hematopoietic tissue47, as similarly observed in
humans48. However, high embryonic EPOR expression in the
brain decreases ~20-fold over 10 days leading up to birth49. Here
we show in adult mice that transcriptional EPOR expression in
the brain is lower than the spleen by approximately eight orders
of magnitude. Since EPOR expression closely relates to cellular
EPO sensitivity, the relatively high concentrations of EPO in the
brain achieved in this study by means of transgene or high-dose
EPO injections are suggested to be essential for promoting
mitochondrial development in the hippocampus of mice.
Intracellular EPO/EPOR signaling acts through multiple
pathways including Erk1/2, AKT, and Janus kinase/signal trans-
ducers and activators of transcription (JAK/STAT). Analysis in
this study focused on AKT and Erk1/2 pathways, as they are more
Fig. 5 Intraperitoneal (i.p.) EPO injections in WT mice resulted in greater pAKT, pErk1/2, higher rates of respiration, and more mitochondrial content
in the hippocampus. a Schematic diagram of EPO (red bars) or saline (white bars) treatment in mice. Male animals were injected for three consecutive
days after weaning (P23 to P25) with either recombinant human (rh)EPO (5 IU/g) or saline solution. At P26 hippocampal tissue was taken for
respirometry and protein analysis. b Changes in hematocrit (%) after treatment; unpaired t-test, ****p < 0.0001. c Representative images of total AKT, total
Erk1/2, and voltage-dependent anion channel 1 (VDAC1) protein expression with vinculin as a loading control. d Quantification of AKT normalized to
vinculin and saline; unpaired t-test, *p= 0.049. e Quantification of Erk1/2 protein expression normalized to vinculin and saline; unpaired t-test, p= 0.26.
f Quantification of VDAC1 protein expression normalized to vinculin and saline; unpaired t-test, **p < 0.004. g Representative images of total
phosphorylated pAKT and pErk1/2 protein expression with vinculin as a loading control. h Quantification of pAKT normalized to vinculin and saline;
unpaired t-test, *p= 0.03. i Quantification of pErk1/2 normalized to vinculin and saline; unpaired t-test, *p= 0.012. j Cytochrome C oxidase activity (COX,
pmol O2/s * mg ww) in the hippocampus of WT mice randomly treated with either saline or EPO (5 IU/g). EPO-treated mice show higher COX activity;
unpaired t-test ***p= 0.0006. k Hippocampal mass-specific oxygen consumption rates (OCR) fromWT control (saline) and EPO (5 IU/ml) injected mice.
PCI respiration, PCI+CII respiration, and ECI+CII respiration is increased in EPO-treated mice; 2-way ANOVA, F(1,56)= 40.27, ****p < 0.0001, with multiple
comparisons: *p < 0.05, ***p < 0.001, and ****p < 0.0001. l Mitochondria-specific OCR (mass-specific OCR normalized to COX activity, a surrogate for
mitochondrial content). No differences in mitochondria-specific respiration are observed between saline and EPO-treated mice; 2-way ANOVA, F(1,56)=
0.77, p= 0.38. Barplots with SD bars.
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commonly reported as key regulating pathways in mitochondrial
biogenesis, mitochondrial dynamics, and metabolic control25–28.
Here we show that constitutive overexpression of cerebral EPO,
as well as high-dose i.p EPO injections shown to traverse the
blood–brain barrier41, increased pErk1/2 and pAKT levels in the
hippocampus with negligible changes in total respective protein
expression. During the early postnatal period, ERK participates in
the maturation process of dendritic trees and synaptogenesis in
Fig. 6 EPO overexpression in CNS upregulates PGC1-1α, alters control of mitochondria dynamics, increases mitochondria size, increases mitochondria
number, and increases the number of vesicles in presynaptic terminals of the hippocampus. a PGC-1α mRNA expression in hippocampus from WT and
Tg21 mice. PGC1α increases with age in both genotypes; 2-way ANOVA, F(3,24)= 46.93, ****p < 0.0001. At P21, a higher expression is observed in Tg21
mice; LSD post hoc, *p= 0.03. b ATG5 mRNA expression in hippocampus from WT and Tg21 mice. ATG5 demonstrates age-dependent increases with no
difference between genotypes; 2-way ANOVA, F(3,24)= 11.98, ****p= 0.0001. mRNA expression of pro-fusion: c Mitofusin 2 (MFN2) and d mitofusin 1
(MFN1), and of pro-fission: e dynamin 2 (DNM2), and f dynamin-related protein 1-dynamin 1 (DRP1-DNM1) in WT and Tg21 hippocampus. Transcriptional
control of fusion (both MFN1 and MFN2) is enhanced in Tg21 mice at P21; 2-way ANOVA: MFN1, F(1,24)= 1,143, *p= 0.30; and MFN2, F(1,24)= 7.216,
**p= 0.01. An age-dependent increase inMFN2 is observed in both genotypes; 2-way ANOVA, F(3,24)= 48.59, ***p < 0.001. Pro-fission DNM2 shows no
change in expression across development nor between genotypes; 2-way ANOVA, F(1,24)= 0.37, p= 0.54. Pro-fission DRP1-DNM1 is higher in Tg21 at
P21; 2-way ANOVA, F(1,24)= 8.834, **p= 0.007. p. a–f Relative mRNA expression levels of the aforementioned genes are quantified by qPCR and
normalized to ACTB. g Representative electron microscope (EM) images of hippocampal CA1 area from WT and Tg21 mice at P14. More mitochondrial
profiles (yellow arrows) and a higher number of vesicles in presynaptic axon terminals are observed in Tg21 mice. Scale bar: 1 μm (right panels) and 100 nm
(panel insets). h Quantification of mitochondria number in the total field of view; unpaired t-test, *p= 0.036. i Mitochondria size; unpaired t-test, p=
0.002. j Mitochondria total mass in presynaptic terminals; unpaired t-test, **p= 0.0043. k Vesicle numbers in presynaptic terminals; unpaired t-test, ****p
< 0001. Barplots with SD bars.
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the hippocampus50. During neural differentiation, Erk1/2 signal-
ing is associated with increased transcriptional expression of
PGC-1α51. However, Erk1/2 generally promotes mitochondrial
fission via DRP1 phosphorylation of S616 and suppressing MFN1
via phosphorylation of T56227,28 under pro-apoptotic
conditions52. Alternatively, AKT promotes a hyperfused mito-
chondrial network by suppressing DRP1 with reciprocal phos-
phorylation of DRP1 at S637 and reducing phosphorylation of
S616 via proto-oncogene serine/threonine-protein kinase (Pim-
1)53. EPO-activated AKT increases mitochondrial biogenesis
through eNOS by which an increase in nitric oxide (NO) upre-
gulates PGC-1α, as observed in cardiomyocytes25,26. The
mechanistic/mammalian target of rapamycin complex 1
(mTORC1) has also been shown to upregulate mitochondria and
increase respiration via inhibition of the eukaryotic translation
initiation factor 4E (eIF4E)-binding proteins (4EBPs)54, and both
Erk1/2 and AKT signaling promote the activation of mTORC1.
Thus, EPO-EPOR signaling through Erk1/2 and AKT pathways
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Fig. 7 EPO enhances hippocampal-dependent spatial navigation and improves short-term memory. aMorris water maze (MWM) tests was performed in
WT and Tg21 mice at early adulthood (P48-60). Outcome variables relating to the acquisition phase (upper panels) and reversal phase (lower panels) are
shown. Circular insets show the position of the hidden platform in the water maze. Escape latency (s) is quicker (2-way ANOVA, F(1,22)= 28.18, ***p < 0.001),
swim path length (m) is equal (2-way ANOVA, F(1,22)=0.85, p=0.36), and swim speed (m/s) is faster (2-way ANOVA, F(1,22)= 62.4, ****p < 0.0001) in
Tg21 mice during acquisition. During reversal, time in the training quadrant was higher in Tg21 mice; 2-way ANOVA, F(1,22)= 105, ****p < 0.0001. Tg21 animals
demonstrated shorter scape latency (s), 2-way ANOVA, F(1,22)= 10.8, ***p < 0.001, shorter swim path length (m), 2-way ANOVA, F(1,22)= 12.1, **p < 0.01,
and faster swim speed (m/s), 2-way ANOVA, F(1,22)= 18.6, ****p < 0.0001 than WT controls during reversal. Multiple comparison: *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001. b Representative diagram of the Novel Object Recognition (NOR) test, as fully explained in the methods. Object recognition
relating to short-term memory function using 1 h inter-trial-intervals (ITI) and long-term memory function using 24 h ITI is shown with object discrimination
index. Tg21 animals demonstrated longer total exploration time and an improved discrimination index when testing short-term memory. Animals from both
genotypes appeared to recognize the replaced object equally when testing long-term memory; 2-way ANOVA, F(1,68)= 6.18, **p=0.01. c T-maze spatial
working-memory test shows spontaneous alternation above 75% in WT and Tg21 mice. Tg21 mice make less errors than WT at the second and third test from
each day reflecting a better short-term but no improvement in long-term memory as observed in t4 after 24 h; 2-way ANOVA, F(1.132)= 14.17, ***p=0.0003.
Multiple comparisons, ***p < 0.001, and ****p < 0.0001. Barplots with SD bars.
Fig. 8 Illustrative summary of proposed EPO functions in hippocampal CA1 pyramidal cells at postnatal ages P14 and P21. Hippocampal CA1 pyramidal
cells are represented by triangles. When EPO-EPOR binding increases (e.g., Tg21 animals or WT mice treated with high doses of EPO), increased
phosphorylation of Erk1/2 and AKT precedes an increase in mitochondria content, size, and function. More mitochondria are also observed in presynaptic
terminals, along with an increase in vesicle numbers. As a result, animals with greater hippocampal respiratory potential show enhanced spatial learning
and short-term memory at adulthood. (Figure created with BioRender.com).
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could increase hippocampal mitochondria and respiratory
potential.
High-resolution respirometry analyses demonstrated higher
OCR for 3 different respiratory states (PCI, PCI+CII, and ECI+CII)
during postnatal development (P14 and/or P21) in Tg21 mice as
well as P26 WT mice treated with EPO when compared to their
respective control groups. Additionally, COX activity, ratio of
mtDNA to nDNA, an assortment of mitochondrial proteins, as
well as mitochondrial number and size assessed via electron
microscopy were all greater with EPO. The higher respiratory
potential with EPO appears to result from quantitative mito-
chondrial increases/expansion and not qualitative alterations in
respiratory control, as differences in mass-specific OCR were lost
when normalizing respiration to a surrogate of mitochondrial
content (e.g., COX activity).
Transcriptional promotion of mitochondrial biogenesis was
also higher in Tg21 animals as evidenced by more hippocampal
PGC-1α mRNA at P21. Astrocyte differentiation and synapto-
genesis have been shown to be influenced by PGC-1α in the
postnatal prefrontal cortex55. We have also previously shown
EPO-facilitated improvements in synaptogenesis during post-
natal hippocampal development39. Thus, EPO-directed PGC-1α
upregulation may influence synaptogenesis in the hippo-
campus. Transcriptional control of mitochondrial dynamics in
the hippocampus was also altered with EPO, as pro-fusion
(MNF1 and MNF2) and pro-fission (DRP1-DNM1) signals were
higher at P21. Recent evidence identified distinct DRP1-
mediated signaling profiles that result in mitochondrial degra-
dation or biogenesis in which the origin of fission differs56.
Midzone mitochondrial fission promotes mitochondrial pro-
liferation whereas peripheral mitochondrial fission sequesters
dysfunctional components of the organelle for mitophagic
control. Although we are unable to verify the specific fission
profiles or origins of fission in the current study, peripheral
fission is preceded by evidence of mitochondrial dysfunction
(i.e., oxidative stress, drop in membrane potential, and/or loss
of proton motive force) as well as lysosomal-mitochondrial
contact56. Respirometric analyses in the current study suggest
no difference in ROS production (LN state respiration) as well
as greater membrane potential and proton motive force in Tg21
and EPO-treated WT mice (PCI, PCI+CII, and ECI+CII respira-
tion). Also, we found no indication of the difference in lyso-
somal activation as evidenced by the transcriptional consistency
of ATG5 between genotypes throughout postnatal development.
Given these findings, along with the observations that mito-
chondrial number and size were greater in Tg21 vs WT con-
trols, EPO appears to increase mitochondrial biogenesis in the
hippocampus early in life.
Mitochondrial plasticity is a key factor in metabolic adaptation,
and alterations in shape and content can reflect changes in
respiratory potential. Greater mitochondrial content was
observed specifically in presynaptic terminals in combination
with increased vesicle numbers at P14 in Tg21 mice. Although
total vesicle number in synaptic terminals were counted and
reported, not just reflecting those in contact with the active zone,
synaptic vesicles are recruited to the active zone to discharge
neurotransmitters during intense stimulation. This process is
dependent on mitochondrially derived ATP57. Therefore, higher
OCR and mitochondrial content in presynaptic neurons suggest a
higher energetic potential to support greater vesicle release. A
greater number of glutamatergic and GABAergic synapses and
increased inhibitory postsynaptic current amplitude reported at
P14 in Tg21 mice39 also support the concept that increased
respiratory potential is coupled with more synaptogenesis during
postnatal development, and these EPO-facilitated differences may
enhance cognition.
Mitochondrial dysfunction leads to severe defects in
hippocampal-dependent cognitive function, such as memory and
learning58, associated with several neurodevelopmental disorders
and degenerative diseases59,60. EPO has been shown to be an
effective drug to restore mitochondrial dysfunction and cognition
after brain traumatic injury61 and in neurodegeneration11,62–65.
EPO treatment improves neuronal mitochondrial activity and
upregulates brain hemoglobin expression in mouse models of
multiple sclerosis (MS)35. It is therefore likely that EPO over-
expression causes an increase in neural hemoglobin during
development stimulating neuronal mitochondrial function. Our
paired observations of concentrated EPOR expression on
CA1 cells39 and higher rates of cellular respiration in the hip-
pocampus of Tg21 mice led us to speculate that EPO over-
expression may also improve hippocampal-mediated cognition.
It is well documented that EPO administration or over-
expression enhances spatial memory across several models of
disease30,35,36,66. Hippocampal CA1 principal cells have a well-
defined role as being cognition-relevant but hypoxia-vulnerable67.
Mitochondrial function, especially as it pertains to the hippo-
campus, has also been shown to influence spatial memory
throughout life68,69. Spatial memory and short-term memory
were tested using the MWM, NOR, and T-maze spatial working-
memory tests. The MWM test showed significantly shorter escape
latency during acquisition and reversal phases with reduced swim
path length. These measures were all influence by the genotypic
difference in task performance speed. We previously reported
improved exercise performance in Tg21 mice with a longer time
to exhaustion that was independent of systemic hematological
differences (e.g., hematocrit)70. Perhaps the faster swim speed
observed in the current study could be partially explained by the
diminished influence of central fatigue on physical function in
Tg21 animals, as metabolic control in the brain plays a critical
role in limiting maximal exercise capacity71. While higher mito-
chondrial content was observed in Tg21 mice earlier in life (P14-
21), maximal coupled respiration, PCI+CII, the respiratory state
that best reflects in vivo oxidative phosphorylation potential, did
not differ between WT controls and Tg21 mice at P60. Moreover,
the shorter swim path length of Tg21 mice to find the platform,
suggests improved spatial orientation most likely attributed to
enhanced plasticity as shown previously13,16,72. The NOR test
with spatial cues examined the influence of EPO on short-term
and long-term memory. Throughout the training phase, Tg21
mice showed increased activity, but total exploration time was
like WT controls. Ultimately, our findings suggest that EPO
overexpression may improve short-term memory, but long-term
memory remains uninfluenced. The role of the hippocampus,
cerebral cortex, and their integrated communication in develop-
ing short- and long-term memory is not fully understood.
However, the neural mechanisms used to establish short- and
long-term memory are known to be somewhat independent73.
While we cannot currently provide a clear description explaining
the disparate influence of EPO on short- and long-term memory,
our observations suggest a role for EPO to enhance short-term
memory. Finally, T-maze spatial working memory showed no
differences in total spontaneous alternation between genotypes,
but Tg21 mice were faster in the choice and made fewer errors in
the second and third test from each day, further reflecting
improved learning and short-term memory.
In this study, we provide insights on the mechanisms by which
EPO may enhance cognition in early life. We show that EPO
signaling through Erk1/2 and AKT corresponds with improve-
ments in respiratory potential and mitochondrial content, such as
the greater number and size of mitochondria identified in pre-
synaptic terminals of the hippocampus, which are observable by
the second postnatal week of development. This enhanced
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energetic potential could support greater synaptogenesis and
provide a cognitive advantage later in life. Indeed, constitutive
expression of cerebral EPO also improved spatial and short-term
memory in early adulthood. These findings highlight a ther-
apeutical potential of EPO to stimulate hippocampal metabolism
during maturation, which may improve neurodevelopment and
cognition in, for example, premature children afflicted with
hippocampal dysfunction following neonatal hypoxic-ischemic
brain injury.
Methods
Animals. Mitochondrial analyses were conducted with both sexes using WT
controls and transgenic Tg2174,75, mice at postnatal (P) ages: 3, 7, 14, 21, and 60
(n= 8). Behavioral tests were performed in early adulthood (P45–60). Tg21
hemizygous mice were backcrossed with C57Bl/6 mice for more than ten gen-
erations to obtain the corresponding control mice and Tg21 mice were bred to
homozygosity.
All mice were bred and housed under standard conditions at the University of
Zurich. Animals were kept on a 12/12-h light/dark cycle with food and water
provided ad libitum. Animal experiments were performed following the ARRIVE
guidelines and were approved by the Cantonal Veterinary Office of Zurich,
Switzerland (ZH177_16).
EPO intraperitoneal injections. Male mice received i.p. injections with 5 IU/g
rhEPO (NeoRecormon, Roche) or placebo (saline solution) for three consecutive
days. EPO/saline treatment was initiated in P23 animals. Animals were sacrificed at
P26, 24 h after the last treatment followed by respirometry or tissue collection for
later protein analyses.
Blood samples for measures of hematocrit, hemoglobin, and plasma EPO.
Mice were anesthetized with a subcutaneous injection containing 100 mg/kg
ketamine (Ketasol-100; Dr. Graub, Switzerland), 20 mg/kg xylazine (Rompun;
Bayer, Germany), and 3 mg/kg acepromazine (Sedalin, Switzerland). Blood samples
were taken by cardiac puncture with a 27 G needle attached to a 1 ml heparinized
syringe. The blood was immediately transferred into an Eppendorf tube (1 ml) to
determine hematocrit, hemoglobin, and plasma EPO concentrations.
Duplicate measures of hematocrit were collected using microcapillary tubes
(Micro haematocrit tube 100, Assistant) and immediately centrifuged (Hettich,
Tuttlingen, Germany) for 5 min at 104 rpm (Autokit II, Pharmap, Geneva,
Switzerland). Hemoglobin concentration was determined using Abbott Cell Dyn
3500 (Abbott Diagnostic Division, Santa Clara, CA, USA). For assessing EPO in
plasma, blood was collected in pre-cooled EDTA tubes, immediately spun for 10
min at 1500×g in a cooled centrifuge, plasma was collected and transferred to dry
ice. All plasma samples were kept at −80 °C until assayed. Plasma EPO
concentrations were assessed using a commercial radioimmunoassay (RIA) kit
(Epo-TracTM125I RIA kit; DiaSorin, USA). A known concentration of EPO
antibody is incubated with 125-I radiolabelled antigens for binding. Blood plasma
is added and unlabeled EPO antigens from plasma compete with the radiolabelled
antigens for antibody binding sites. The higher the concentration of the EPO
plasma antigens, more binds to the antibodies displacing more free radiolabelled
antigens to the media. Radioactivity of the media is measured using a gamma
counter (Quanta Smart for Tri-Carb 4910TR, PerkinElmer).
Measurement of mouse EPO (mEPO) and recombinant human EPO (rhEPO)
in brain, kidney, liver, and spleen tissues. Concentrations of rhEPO were
determined from frozen samples of brain, kidney, liver, and spleen from WT (P5)
and Tg21 (both P5 and P21) mice using a commercial kit (Quantikine IVD ELISA,
human erythropoietin, R&D Systems). Fresh wet weights of brain and spleen
samples were registered for comparison.
mEPO and rhEPO levels in the brain were additionally assessed at P60 in WT
and Tg21 mice using commercial kits (Quantikine ELISA, mouse erythropoietin,
and human erythropoietin, R&D systems).
Measurement of hippocampal EPO protein expression. Hippocampal EPO from
WT and Tg21 mice was assessed in snap-frozen samples throughout development
using a radioimmunoassay (RIA) kit (Epo-Trac 1251 RIA kit; DiaSorin, Saluggia,
Italy) as previously described76.
DNA extraction and mitochondrial copy number. To extract genomic and
mitochondrial DNA, 5–10 mg hippocampal tissue was digested by 100 µg/ml
proteinase K in a lysis buffer (50 mM KCl, 10 mM Tris-HCl pH 8.3, 10 µg/ml
gelatin, 0.045% Nonidet P-40, 0.045% Tween 20) at 55 °C overnight. After heat
inactivation of proteinase K and centrifugation to remove cellular debris, DNA was
precipitated by sodium acetate and ethanol. After centrifugation, DNA pellets were
air-dried then resuspended in nuclease-free water. DNA concentration was ana-
lyzed using Nanodrop 2000 (ThermoFisher Scientific). The amount of
mitochondrial DNA (mtDNA) in tissue was estimated by the ratio of the mito-
chondrial MT-ND1 gene copy number and the nuclear N-B2M gene copy
number77,78. Primers against both genes (Table 1) and SYBR Green (ThermoFisher
Scientific, #A25741) were used for a semi-quantitative analysis by quantitative real-
time PCR (7500 Fast Real-Time PCR System, ThermoFisher Scientific). The ratio
of genomic (N-B2M gene) and mitochondrial (MT-ND1) DNA was determined by
the ΔΔCt method79.
RNA extraction and mRNA expression analyses. Five-to-ten mg of hippocampal
and cortical tissues from both genotypes (WT and Tg21) and sexes (male and
female) brain tissue at P3, P7, P14, and P21 were used to extract RNA using
ReliaPrep RNA Tissue Miniprep System (Promega, #Z6110). Purity was deter-
mined spectrophotometrically (Nanodrop 2000, ThermoScientific). First-strand
cDNA was obtained by reverse transcription using RevertAid First Strand cDNA
Synthesis Kit (ThermoFisher Scientific, #K1622). Samples (5 ng/µl cDNA) were
analyzed by a SYBR Green (ThermoFisher Scientific, #A25741) semi-quantitative
real-time PCR (qRT-PCR) (7500 Fast Real-Time PCR System, ThermoFisher
Scientific). Primers for mRNA expression analyses were designed with Primer 3.0.
Software to amplify either human or murine genes without cross-specificity
(Table 1). Oligo properties were calculated using Oligo Analyzer 3.1. Before using
primers for mRNA expression analyses, they were validated by qRT-PCR by (i)
melting curve analyses (mode integrated in the 7500 Fast Real-Time PCR System)
as well as on (ii) acrylamide gels to confirm the size and purity of PCR products.
mRNA expression levels were calculated using the ΔΔCt method79 and normalized
to either ACTB or GAPDH. Each group of samples was normalized to WT P3
hippocampus. Annealing temperatures are shown in Table 1.
Western blot analysis. Brain tissue samples from both sexes were collected from
WT and Tg21 mice at P3, P7, P14, P21, and P60. Animals were deeply anesthetized
with an i.p. injection of sodium pentobarbital (50 mg/kg; Nembutal, Kantonsa-
potheke Zürich) followed by decapitation and dissection of brain tissue on ice.
Hippocampus and caudal cortex were dissected and placed on ice. Samples from
each animal were independently processed (n= 4 animals/group). Total hippo-
campal tissue was homogenized by transferring the tissue through a 21 G needle 5
times in ice-cold 300 µl RIPA buffer (50 mM Tris/HCl pH 8.0, 150 mM NaCl, 1%
NP-40, 0.5% Na deoxycholate, 1 mM EDTA, 0.1% SDS) with Protease Inhibitor
Cocktail Set III, EDTA-Free diluted 1:100 (Merck Millipore, #539134), 1 mM
Sodium orthovanadate, and 20 mM sodium fluoride as tyrosine and serine/threo-
nine phosphatases inhibitors. Samples were kept on ice for 30 min and whole-cell
lysates were collected after centrifugation at 13,000 rpm for 10 mins at 4 °C. Protein
concentrations were determined using a Pierce BCA assay (ThermoScientific,
#23228, #23224). Loading samples (4×) were prepared by boiling at 70 °C for 5 min
in a Laemmli buffer (4% SDS, 20% glycerol, 10% mercaptoethanol, 0.004% bro-
mophenol blue, and 0.125 M Tris-HCl pH 6.8). Protein samples (40 µg) were run
in 10% (for AKT, pAKT, Erk1/2, pErk1/2, and VDAC1 proteins) or 12.5% (for
mitochondrial electron transport system proteins) SDS-PAGE gels (Bio-Rad, USA)
for 90 min at 18 mA. Samples were then transferred for 1–2 h at 120 V to 0.45 µm
nitrocellulose blotting membrane (GE Healthcare, #10600002) using TE62 Transfer
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tank with a cooling chamber (HoeferTM, USA). Membranes were washed 2× for 10
min with 0.05% TBST followed by blocking in 5% skimmed milk or bovine serum
albumin (BSA) in 0.05% TBST for 1 h at room temperature. BSA was used for
membrane blocking with phosphoprotein staining. Membranes were incubated at
4 °C overnight with the following primary antibodies diluted 1:1000 in 5% skim-
med milk or BSA in 0.05% TBST solution: rabbit anti-p44/42 MAPK (Erk1/2) (Cell
Signaling, #9102); rabbit anti-Phospho-p44/42 MAPK (pErk1/2) (Cell signaling,
#9101); mouse anti-AKT(pan) (Cell Signaling, #9272); 1:1000 rabbit anti-Phospho-
AKT(Ser473) (Cell Signaling, #9271); rabbit anti-VDAC1/Porin antibody (Abcam,
#ab15895). Membranes were incubated at a 1:250 in OxPhos Rodent WB Antibody
Cocktail (ThermoFisher Scientific, #458099), and rabbit anti-COX-IV monoclonal
antibody (3E11) (Cell Signaling, #4850). Membranes were washed and incubated in
horseradish peroxidase-(HRP) conjugated secondary antibodies, goat anti-rabbit
IgG (Merck, 12–348), and goat anti-mouse IgG (Santa Cruz, #2032), diluted 1:3000
in 5% milk in 0.05% TBST. Bands were visualized using Super Signal West Femto
(ThermoScientific, #34095) and developed with FUJIFILM Intelligent Darkbox
Las-3000. Secondary antibody solutions conjugated to fluorescent molecules for
two-color detection of AKT and pAKT proteins (anti-mouse IRDye 680 LT red and
anti-rabbit IRDye 800CW green, respectively), diluted 1:8000 in 5% BSA in 0.05%
TBST blocking solution for 1 h at room temperature.
Protein loading was controlled with a mouse monoclonal antibody anti-β-actin
(Sigma, #A5316) for AKT and electron transport system proteins or a rabbit anti-
vinculin antibody (Abcam, #155120) for Erk1/2 and VDAC1 proteins. Protein
values were analyzed densitometrically with ImageJ (NIH) software. Band
intensities were corrected with values determined on β-actin or vinculin blots and
expressed as relative values compared to WT mice.
Detection and analysis of fluorescent bands were completed with the Li-COR
Odyssey Platform (Biosciences).
High-resolution respirometry
Tissue sampling. Hippocampal tissue samples were collected from WT and Tg21
animals at postnatal ages P3, 7, 14, 21, and 60. Samples were blotted dry, assessed
for wet weight in a balance-controlled scale (Dual Range Analytical Balance,
Mettler Toledo AG, Switzerland), maintaining constant relative humidity and
hydration consistency for the stability of measures, and immediately immersed in
ice-cold respiration medium MiR05 (110 mM sucrose, 0.5 mM EGTA, 3 mM
MgCl2*6H2O, 80 mM KCl, 60 mM K-lactobionate, 20 mM taurine, 10 mM
KH2P04, 20 mM HEPES, and 1 g/l bovine serum albumin, pH= 7.1)80. All che-
micals were obtained from Sigma-Aldrich (Switzerland).
High-resolution respirometry. Mass-specific (pmol O2/s * mg tissue wet weight)
OCR were collected using a high-resolution Oxygraph-2k respirometer (Oro-
boros, Innsbruck, Austria). Standardized instrumental calibrations were per-
formed to correct for the back-diffusion of oxygen into the chamber from
various internal components, leak from the exterior, oxygen consumption by the
chemical medium, and sensor oxygen consumption. All experiments were car-
ried out in a hyper oxygenated environment (>200 nmol/ml) to prevent any
potential oxygen diffusion limitations and oxygen flux was resolved by software
allowing nonlinear changes in the negative time derivative of the oxygen con-
centration signal (DatLab, Oroboros, Innsbruck, Austria). All measures were
collected at 37 °C in a respiration buffer MiR06 (MiR05 + 280 iU/ml catalase)
with saponin (50 μg/ml) to facilitate cell membrane permeabilization81. All
substrate, uncoupler, and inhibitor titrations described below were added in
series (Fig. 2a).
Respiratory titration protocol. The respiration protocol used examines individual
aspects of respiratory control by initiating a specific sequence of respiratory
states. Here we analyzed various respiratory states representative of mitochon-
drial proton leak (L), maximal rates of coupled oxidative phosphorylation (P),
and maximal rates of uncoupled respiration (E). Each respiratory state is specific
to the substrate(s), uncoupler(s), and inhibitor(s) included in the respiration
medium at any given time in addition to the proton motive force and the
relation of respiration to ATP production. L-state respiration, with kinetically
saturating substrate and oxygen concentrations, represents uncoupled respira-
tion due to proton leak and slippage across the inner mitochondrial membrane
with a maximal proton motive force in the absence of ATP production and is
comparable to the classical definition of either state 2 or 4 respiration82. Mito-
chondrially derived oxidant production is highest during L-state respiration83,84.
P-state respiration, with kinetically saturating substrates, oxygen, and thermo-
dynamically favorable adenylate concentrations to facilitate oxidative phos-
phorylation, represents respiratory rates that are well-coupled to ATP synthesis
with a high proton motive force and are comparable to the classical definition of
state 3 respiration82. E-state respiration, with kinetically saturating substrate and
oxygen concentrations along with optimal exogenous protonophore provision,
represents non-coupled respiratory rates independent of ATP synthesis with a
collapsed proton motive force. Respiratory analysis began with the collection of
L-state respiration without exogenous adenylates (LN) following the addition of
malate (2 mM) and octanoylcarnitine (0.2 mM). P-state respiration driven by
electron input from the electron transfer flavoprotein complex and mitochon-
drial complex I (PETF+CI) was initiated with the addition of ADP (5 mM). As the
brain poorly oxidizes lipid substrates, PETF+CI can serve as an internal control of
sample purity. Indeed, we found negligible changes in respiration between basal,
LN, and PETF+CI respiration (see result section). Accordingly, any reference of
electron input from the electron transfer flavoprotein complex will be excluded
from respiratory state identification throughout the results and discussion. P-
state respiration with maximal NADH-linked electron input from mitochondrial
complex I, PCI, was induced following the additions of pyruvate (5 mM) and
glutamate (10 mM). Maximal rates of P-state respiration, and the best repre-
sentation of maximal oxidative phosphorylation potential in vivo, were then
initiated with the addition of succinate (10 mM), which adds additional electron
input from mitochondrial complex II, PCI+CII. Maximal E-state respiration, ECI
+CII, was achieved with titrations of the protonophore, carbonyl cyanide p-
(trifluoromethoxy) phenylhydrazone (FCCP), in 0.5 μM steps up to an optimum
concentration (ranging from 1.5 to 3 µM). E-state respiration primarily reflect-
ing electron input via mitochondrial complex II was then determined following
the addition of rotenone (0.5 µM) and subsequent inhibition of mitochondrial
complex I. Finally, non-mitochondrial residual oxygen consumption (ROX) was
induced with the addition of antimycin A (2.5 μM) and attendant inhibition of
mitochondrial complex III. All respiratory states were corrected for measures of
ROX. Upon completing respiratory state analyses, ascorbate (2 mM) and N,N,N′,
N′-tetramethyl-1,4-benzenediamine, dihydrochloride (TMPD, 500 μM) were
simultaneously titrated into the chambers to assess cytochrome c oxidase (COX;
complex IV) activity via mass-specific OCR (pmol O2/s * mg ww). Chemical
calibrations were performed to determine and control for the auto-oxidation of
TMPD occurring during measures of COX activity. For this, OCR is assessed
over time using MiRO6 + saponin free of any biological sample with cyto-
chrome c (10 μM), ascorbate (2 mM) and N,N,N′,N′-tetramethyl-1,4-benzene-
diamine, dihydrochloride (TMPD, 500 μM) added to the chamber.
Mitochondria-specific respiration (%) was determined by normalizing mass-
specific respiration (pmol O2/(s*mg ww)) to COX activity (pmol O2/s * mg ww);
(respiratory state respiration/COX activity) * 100.
Electron microscopy
Perfusion and fixation. Mice P14 were i.p. anesthetized with 40 μl pentobarbital (50
mg/ml) and, immediately following loss of pain perception, transcardially perfused
with ice-cold PBS followed by 2.5%PFA/2.5%Gluteraldehyde in 150 ml sodium-
cacodylate solution (0.13 M, pH= 7.4). Brains were removed from the skull and
placed in a 50 ml Falcon tube containing the same fixative for post-fixation for at
least 2 days, at 4 °C.
Tissue block preparation. 80–100 μm thick hippocampal CA1 sections were cut in a
vibratome and kept overnight in Na-cacodylate buffer (0.1 M) at 4 °C.
Osmification. Na-cacodylate buffer was removed from the small PE tube and the
tissues were incubated with 1% Osmium tetroxide (OsO4) solution for 60 min.
Tissues were then washed rapidly twice with Na-cacodylate buffer (0.1 M) and a
third time for at least 30 min.
Dehydration and embedding. Na-cacodylate buffer was substituted with increasing
concentrations of acetone: 1 × 30% acetone, 1 × 50% acetone, 2 × 70% acetone, 2 ×
80% acetone, 2 × 90% acetone; each wash lasted 5 min and 3 × 100% acetone, for 5,
20 and 30min, respectively. Tissues were washed twice with propylene oxide, 5 min
per wash. Afterward, they were incubated in propylene oxide-resin I solution for 40
min at RT. Subsequently, tissues were incubated twice in resin II, which contained
freshly added DMP30 (2,4,6-(Tri-Dimethylaminoethyl-phenol)) for 40 min, at RT.
Tissues were transferred on a glass slide to create the inclusions, covered with
Aclar embedding film (ACLAR®33 C Film, 7.8 Mil, Electron Microscopy Sciences,
Hatfield, PA), and incubated for 48 h, at 60 °C, for resin polymerization.
Cutting of semithin sections. When the resin was completely polymerized, very
small regions of interest were dissected with a blade under the stereomicroscope
(ZEISS, SteREO Lumar.V12) and mounted on small pyramids of resin with glue.
They were left to air-dry overnight.
The mounted tissue was placed on the ultramicrotome (Leica Ultracut EM UC6,
Vienna, Austria) and with a razor-sharp blade, they were given the shape of a
trapezoid. The tissue was then aligned with a glass knife and semithin sections of 1-
µm-thickness were cut. Sections were collected with non-magnetic tweezers and
placed in small drops of ddH2O on gelatinized glass slides. Glass slides were shortly
placed on the heater and when the water drop was completely dried, then the tissue
was contra stained with toluidine blue and observed with the brightfield
microscope. Cutting of thin sections: Thin sections (70 nm thickness) were cut with
a diamond blade and collected in ddH2O and gathered on a nickel grid (diameter:
3.05 mm, G300-Ni, 300 lines/inch square mesh, No. 100, Science Services GmbH,
Munich, Germany). The grids were put in a grid box and air-dried overnight.
Contrasting. A small drop of double distilled water was placed on sections, followed
by drops of uranyl acetate for 7 min, washed with double distilled water; sub-
sequent drops of citrate for 7 min; and wash with double distilled water. Samples
were then left to dry.
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Image acquisition and data analysis. Semithin sections were observed with a
brightfield Axioscope 2 microscope (Carl Zeiss AG, Oberkochen, Germany)
equipped with a color digital camera (AxioCam MRc5) and its corresponding
software, AxioVision 4.5 (Carl Zeiss AG, Oberkochen, Germany), and then EM
micrographs were taken with the 100 kV transmission electron microscope (TEM -
Philips CM100 and Telos) connected to a digital CCD camera.
Mitochondria number, mitochondria size, and vesicle numbers were quantified
in each field of view with automatized particle counter from Fiji ImageJ (National
Institutes of Health, USA).
Cognitive functions tests. Morris water maze (MWM), to test hippocampal-
dependent spatial learning and memory85, novel object recognition (NOR), which
combines spatial and visual memory86, and a T-maze test for assessment of spatial
working memory87 were all performed with male and female animals of both
genotypes at postnatal ages P45–60. After weaning, animals were housed in the
testing room with room a 12 h light/dark inverted cycle and access to food and
water ad libitum in standard laboratory conditions. Mice were controlled three
times per week and handled once weekly to minimize handling-related stress that
could impact performance in the task. Tests were performed during the dark
phase under dimly-lit conditions (12 lux). Animals were video tracked at 4.2 Hz
and 256 × 256-pixel spatial resolution using a Noldus EthoVision 1.96 system
(Noldus Information Technology, Wageningen NL, www.noldus.com) throughout
testing.
Morris water maze (MWM) test (P45–50). The MWM, test to test hippocampal-
mediated spatial memory, was employed as previously described85. The circular
black arena was 150 cm in diameter with a wall height of 50 cm. High contrast
spatial cues were placed on walls of the encompassing room and inside the arena
above the water surface. The arena was filled with water to a height of 15 cm and
maintained at 25 °C. Day 1 consisted of teaching the mice to identify the escapable
endpoint of the task by training them to find a visible Plexiglas platform (16 × 16
cm) placed randomly 0.5 cm underneath the water surface. Days 2–5 consisted of
training the animals to find the hidden platform, which remained in a fixed
position (acquisition phase). Throughout the acquisition phase, the water was
made opaque by the addition of milk and the target platform was hidden 0.5 cm
underneath the water surface 35 cm away from the surrounding walls in one
quadrant (NW, NE, SE, or SW). Animals performed 6 trials of 120 s per day, with
an inter-trial interval (ITI) of 30 min. On day 6, the platform was moved to the
opposite quadrant (reversal phase) and four trials of 120 min were registered to
measure spatial retention. The swim pathway of each mouse was automatically
tracked and the time to reach the platform (escape time), total swim distance (m),
and speed (m/s) were calculated.
Novel object recognition (NOR) test (P52–55). The NOR test relies on the animal’s
intrinsic preference for novelty. The choice to explore a novel object reflects
learning and recognition memory, which also involves the hippocampus88,89
together with cortical areas such as the visual cortex.
Mice were first habituated to an open field-testing arena (60 × 60 × 50 cm) with
two spatial environmental cues on the walls for 10 min on two consecutive days.
Mice were free to explore during habituation and the total activity time was
registered. On the third day, animals were allowed 5 min to explore two equal
objects placed in specific quadrants of the arena. The mice were subsequently
removed from the arena for a 1-h ITI. One of the objects was replaced by another
object similar in height and volume but different in shape and texture. Following
this brief 1-h ITI, mice were reintroduced to the testing arena and allowed to freely
explore the new object for 5 min. The next day (ITI of 24 h), mice were again
allowed to explore the open testing field in the presence of a familiar and another
new object. Time spent exploring each object and the number of explorations was
recorded. An object discrimination ratio was calculated by (1): TN/(TN + TF). TN
= time exploring the new object, TF= time exploring the familiar object. Animals
that explored each object less than 10 s were excluded from the test.
T-maze spatial working-memory test (57–60). Spatial memory was assessed by a
rewarded alternation task in a T-maze made of gray poly-vinyl-chloride/plexiglas
(each arm measures 30 × 10 cm) with a removable central partition and one guil-
lotine door for each arm of the maze. Each mouse was habituated to the T-maze for
two consecutive days before testing by allowing two mice to explore the T-maze
with a food reward (pellets). The test was performed with 6 trials over two con-
secutive days. One trial consisted of two successive runs through the maze. In the
first run (forced run) a food reward (R) was placed in an open arm. The other arm
was closed with a barrier. Mice were then immediately returned to the start arm for
5 s and allowed a second run in which both arms were available, so the animals
could enter either arm (choice run), however, food was available only in the arm
closed on the first run. Consequently, spatial working memory is necessary to
remember which arm was open in the first trial and to alternate. A run was
terminated if a choice was not made within 2 min. The sample arm available to the
mice on the first forced run varied randomly from trial to trial. Following each trial,
the mice were removed from the T-maze and returned to their cage for a 1-h ITI
(short-term memory). This spatial working-memory task is quantified by
spontaneous alternation. The percentage of alternation and time to reach the
reward was calculated per animal.
Statistics and reproducibility. For all statistical evaluations included in this study,
unless otherwise specified, an α of p < 0.05 was considered significant and data are
reported as mean ± SD.
Differences between genotypes (WT vs. Tg21) across ages in protein expression,
mitochondrial respiration, and qPCR (Fig. 1, Supplementary Fig. 1b, d; Fig. 2b–d,
Supplementary Fig. 2, Figs. 3a–d, 4, 5k–l, 6a–f) were determined using a 2-way
ANOVA and post hoc analyses identifying individual group differences were
conducted with Sidak’s correction for multiple comparisons.
Main effects of genotype (WT vs. Tg21) on spleen weight, hematocrit,
hemoglobin, plasma EPO (Supplementary Fig. 1a); mitochondria number (Fig. 6h),
mitochondria size (Fig. 6i), mitochondrial mass in presynaptic terminals (Fig. 6j)
and vesicle numbers (Fig. 5k); were determined using unpaired Student’s t-test.
Comparisons of rhEPO expression in brain, kidney, liver, and spleen in WT and
Tg21 mice (Supplementary Fig. 1c), and the general differences across respiratory
states in WT (Figs. 2e, 3e and Supplementary Fig. 2c, d) and Tg21 mice (Figs. 2f, 3f
and Supplementary Fig. 2c, d), were analyzed with a one-way repeated measures
ANOVA and individual differences identified using Tukey’s HSD post hoc test.
Effects of EPO (i.p.) injections on hematocrit (Fig. 5b), protein expression: AKT
(Fig. 5d), Erk1/2 (Fig. 5e), VDAC1 (Fig. 5f), pAKT (Fig. 5h), pERK1/2 (Fig. 5i); and
COX activity (Fig. 5j) were determined using unpaired Student’s t-test.
The main effects of genotype for outcome variables derived from the behavioral
tests were analyzed using a 2-way ANOVA and post hoc analyses identifying
individual group differences were conducted with Sidak’s correction for multiple
comparisons (GraphPad Prism 8.0.1.).
All tests were performed using Prism 8.0.1. GraphPad Software, San Diego,
CA, USA.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available within the paper and its
supplementary information files. Source data underlying figures are presented in
Supplementary Data 1. Individual data sets generated during the cognitive tests are
available from the corresponding author on reasonable request.
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